Oncology Newswire

Oncology Newswire

Comprehensive Real-Time News Feed for Oncology.

Results 1 - 20 of 19,869 in Oncology

  1. Credit Suisse Group Reiterates 77.00 Price Target for BayerRead the original story w/Photo

    50 min ago | IntersportsWire

    ... prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents. Receive News & Ratings for Bayer Daily ...

    Comment?

  2. Bayer (BAYN) Given a 72.00 Price Target by Nord/LB AnalystsRead the original story w/Photo

    52 min ago | IntersportsWire

    ... prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents. Receive News & Ratings for Bayer Daily ...

    Comment?

  3. Insider Selling: NeoGenomics, Inc. (NEO) Insider Sells $2,351,175.82 in StockRead the original story w/Photo

    3 hrs ago | Daily Political

    NeoGenomics, Inc. insider Steven C. Jones sold 141,127 shares of the firm's stock in a transaction on Wednesday, November 14th. The shares were sold at an average price of $16.66, for a total transaction of $2,351,175.82.

    Comment?

  4. Leerink Swann Equities Analysts Boost Earnings Estimates for Trillium Therapeutics IncRead the original story w/Photo

    5 hrs ago | IntersportsWire

    ... the stock is owned by institutional investors and hedge funds. Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein ...

    Comment?

  5. Zacks Investment Research Upgrades Asterias Biotherapeutics (AST) to BuyRead the original story w/Photo

    6 hrs ago | IntersportsWire

    ... or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. " A number of other equities research analysts have also ...

    Comment?

  6. FY2018 Earnings Estimate for Stemline Therapeutics Inc (STML) Issued By WedbushRead the original story w/Photo

    7 hrs ago | IntersportsWire

    ... biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the ...

    Comment?

  7. Keeping Ahead of the Curve in the Transition to Oncology Value-Based PaymentRead the original story w/Photo

    8 hrs ago | The American Journal of Managed Care

    At a session of The American Journal of Managed Care 's Patient-Centered Oncology Care 2018 meeting, held November 16 in Philadelphia, panelists shared their views on the future of oncology value-based payment models and how they as payers and providers can help advance these models. At a session of The American Journal of Managed Care 's Patient-Centered Oncology Care 2018 meeting, held November 16 in Philadelphia, panelists shared their views on the future of oncology value-based payment models and how they as payers and providers can help advance these models.

    Comment?

  8. Teacher inspires students to support oncology servicesRead the original story w/Photo

    9 hrs ago | Bendigo Advertiser

    ... art department, had not been seen without a facial hair in at least 14 years. They had the opportunity to tour the oncology facilities at Bendigo Health on Friday as they presented their $5402.99 donation. Mrs Heaslip said she had told anyone who ...

    Comment?

  9. Loxo Oncology eyes FDA approval for first drugRead the original story w/Photo

    12 hrs ago | News Times

    Registration will allow you to post comments on newstimes.com and create a newstimes.com Subscriber Portal account for you to manage subscriptions and email preferences. Loxo Oncology Chief Executive Officer Josh Bilenker, left, and Chief Business Officer Jacob Van Naarden pose for a photo inside the company's headquarters at 281 Tresser Blvd., in downtown Stamford, Conn.

    Comment?

  10. New inhibitor which blocks inflammation could also treat sepsisRead the original story w/Photo

    12 hrs ago | EurekAlert!

    ... to cause damage to its own tissues. Professor Thomas Helleday, from the University of Sheffield's Department of Oncology and Metabolism and lead author of the study, said: "When oxygen regulation in our cells goes wrong it can cause damage to our ...

    Comment?

  11. Oppenheimer Analysts Give Celsion (CLSN) a $9.00 Price TargetRead the original story w/Photo

    12 hrs ago | IntersportsWire

    ... SEC filing. Institutional investors own 4.83% of the company's stock. Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA ...

    Comment?

  12. Biocept (BIOC) Rating Lowered to Hold at ValuEngineRead the original story w/Photo

    13 hrs ago | IntersportsWire

    ... owned approximately 1.74% of Biocept at the end of the most recent quarter. Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays ...

    Comment?

  13. New Technique Allows for Live Retinal Cell ImagingRead the original story w/Photo

    14 hrs ago | Medgadget

    ... ; ellenastewart123@gmail.com We welcome you all to the International Conference on Oncology and Cancer Science to be held during November 19-21, 2018 We welcome you all to the International Conference on Oncology and Cancer Science to be held during ...

    Comment?

  14. Analysts' Weekly Ratings Changes for AEterna ZentarisRead the original story w/Photo

    15 hrs ago | IntersportsWire

    They now have a $3.00 price target on the stock. According to Zacks, "AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology.

    Comment?

  15. Women's Excellence in Rochester, Michigan Now Offers Treatment Plans for Women with Pelvic PainRead the original story w/Photo

    15 hrs ago | PRWeb

    In addition to oncology services, the new center will specialize in the diagnosis and treatment of various pelvic pain disorders including endometriosis, menorrhagia , uterine fibroids, and uterine and pelvic adhesions . Women's Excellence in Rochester, Michigan, will now offer treatment options to patients suffering from chronic pelvic pain.

    Comment?

  16. EyeQue VisionCheck At-Home Eye Test for Self-Prescription of GlassesRead the original story w/Photo

    16 hrs ago | Medgadget

    ... ; ellenastewart123@gmail.com We welcome you all to the International Conference on Oncology and Cancer Science to be held during November 19-21, 2018 We welcome you all to the International Conference on Oncology and Cancer Science to be held during ...

    Comment?

  17. AstraZeneca Shows It Can Still Take Some KnocksRead the original story w/Photo

    Yesterday | The Washington Post

    ... survival rates in late-stage, non-small cell lung cancer when used in combination with another of its immuno-oncology treatments. Hopes for the pairing were already low: last year, they failed in another trial. Rewind four years, and immuno-oncology ...

    Comment?

  18. Ipsen S a/S (Ipsey) Getting Somewhat Positive Press Coverage, Study FindsRead the original story w/Photo

    Yesterday | AmericanBankingNews.com

    ... company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rheumatology areas. Its products include Somatuline, ...

    Comment?

  19. Purdue researchers look to make chemotherapy more bearableRead the original story w/Photo

    Yesterday | WLFI-TV West Lafayette

    ... Control and Prevention reports that each year, about 650,000 cancer patients receive chemotherapy in an outpatient oncology clinic in the United States. She said this will hopefully make chemotherapy more bearable. She has a team of 12 students who ...

    Comment?

  20. Oncobiologics (ONS) Sets New 1-Year Low at $0.57Read the original story w/Photo

    Yesterday | IntersportsWire

    ... on identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics in immunology and oncology disease areas. Its advanced product candidate is ONS-3010, an adalimumab biosimilar that is in a Phase 1 clinical trial, which ...

    Comment?